Annovis Bio to Present Phase 3 Parkinson’s Data at Parkinson Study Group Annual Meeting
Annovis Bio Inc. will present Phase 3 data on buntanetap's effects in Parkinson’s disease dementia at the 2025 Parkinson Study Group Annual Meeting in San Diego. The presentation, led by CEO Maria Maccecchini, will focus on cognitive outcomes and biomarker improvements. The event is scheduled for December 5 at 6:15 p.m. PST.
Annovis Bio Inc. will present at the 2025 Annual Meeting of the Parkinson Study Group, taking place from December 4-6, 2025, in San Diego, California. The company will showcase new data on buntanetap’s effects in Parkinson’s disease dementia patients, focusing on cognitive outcomes and biomarker improvements, with a poster guided tour led by President and CEO Maria Maccecchini scheduled for December 5 at 6:15 p.m. PST. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annovis Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9595762-en) on December 03, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
